| 1. |
|
|
| 2. |
- Grigorescu, F, et al.
(författare)
-
HAPLOGENDIS INITIATIVE - SICA
- 2009
-
Ingår i: ACTA ENDOCRINOLOGICA-BUCHAREST. - : ACTA Endocrinologica Foundation. - 1841-0987 .- 1843-066X. ; 5:1, s. 143-148
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
|
|
| 3. |
- Maierbeck, P., et al.
(författare)
-
Probing the single particle structure around Ca-54 with one-neutron knock-out
- 2008
-
Ingår i: AIP Conference Proceedings. - 1551-7616 .- 0094-243X. ; 1012, s. 89-93
-
Konferensbidrag (refereegranskat)abstract
- The nuclei Ca-47 and Ti-55 were populated in one-neutron knock-out reactions at relativistic energies. Momentum distributions of the residual nuclei as well as gamma-ray spectra were measured at the GSI fragment separator (FRS). Preliminary results of the ongoing analysis including cross sections and spin/parity assignments are presented.
|
|
| 4. |
- Maierbeck, P., et al.
(författare)
-
Structure of 55Ti from relativistic one-neutron knockout
- 2009
-
Ingår i: Physics Letters B. - : Elsevier BV. - 0370-2693. ; 675:1, s. 22-27
-
Tidskriftsartikel (refereegranskat)abstract
- Results are presented from a one-neutron knockout reaction at relativistic energies on 56Ti using the GSI FRS as a two-stage magnetic spectrometer and the Miniball array for gamma-ray detection. Inclusive and exclusive longitudinal momentum distributions and cross-sections were measured enabling the determination of the orbital angular momentum of the populated states. First-time observation of the 955(6) keV -hole state in 55Ti is reported. The measured data for the first time proves that the ground state of 55Ti is a 1/2- state, in agreement with shell-model calculations using the GXPF1A interaction that predict a sizable N=34 gap in 54Ca.
|
|
| 5. |
- Goadsby, Peter, et al.
(författare)
-
Almotriptan and zolmitriptan in the acute treatment of migraine
- 2007
-
Ingår i: Acta Neurol Scand. ; 115:1, s. 34-40
-
Tidskriftsartikel (refereegranskat)abstract
- OBJECTIVE: To compare almotriptan and zolmitriptan in the treatment of acute migraine. METHODS: This multicentre, double-blind trial randomized adult migraineurs to almotriptan 12.5 mg (n = 532) or zolmitriptan 2.5 mg (n = 530) for the treatment of a single migraine attack. The primary end point was sustained pain free plus no adverse events (SNAE); other end points included pain relief and pain free at several time points, sustained pain free, headache recurrence, use of rescue medication, functional impairment, time lost because of migraine, treatment acceptability, and overall treatment satisfaction. RESULTS: No significant difference was seen in SNAE (almotriptan 29.2% vs zolmitriptan 31.8%) or the other efficacy end points measured. The incidence of triptan-associated AEs and triptan-associated central nervous system AEs was significantly lower for patients receiving almotriptan compared to zolmitriptan. CONCLUSIONS: Almotriptan and zolmitriptan were associated with similar efficacy and overall tolerability in the treatment of acute migraine. Almotriptan was associated with a significantly lower rate of triptan-associated AEs.
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
- Rueda, Blanca, et al.
(författare)
-
Analysis of IRF5 gene functional polymorphisms in rheumatoid arthritis
- 2006
-
Ingår i: Arthritis and Rheumatism. - : Wiley. - 0004-3591 .- 1529-0131. ; 54:12, s. 3815-3819
-
Tidskriftsartikel (refereegranskat)abstract
- OBJECTIVE: Recent findings suggest that interferon regulatory factor 5 (IRF-5) may play a crucial role in several cellular processes, including the transcription of genes for inflammatory cytokines. Two genetic variants of the IRF5 gene (rs2004640 in exon 1 and rs2280714 in the 3'-untranslated region) have been shown to exert functional modifications affecting IRF5 messenger RNA splicing and expression, and have been associated with genetic predisposition to systemic lupus erythematosus (SLE). The aim of this study was to analyze the possible contribution of the IRF5 gene to the predisposition to rheumatoid arthritis (RA). METHODS: Three case-control cohorts from Spain (724 RA patients and 542 healthy controls), Sweden (281 RA patients 474 healthy controls), and Argentina (284 RA patients and 286 healthy controls) were independently analyzed. Genotyping for IRF5 rs2004640 and rs2280714 was performed using a TaqMan 5' allele-discrimination assay. RESULTS: In the 3 cohorts studied, no statistically significant differences in allele or genotype frequencies of the rs2004640 and rs2280714 IRF5 polymorphisms were observed between RA patients and controls. Accordingly, haplotype analysis revealed that none of the IRF5 haplotypes was associated with genetic predisposition to RA. CONCLUSION: Our results suggest that the IRF5 functional polymorphisms analyzed do not seem to be implicated in genetic susceptibility to RA.
|
|
| 9. |
- Rönnblom, Lars, et al.
(författare)
-
The innate immune system in SLE : type I interferons and dendritic cells
- 2008
-
Ingår i: Lupus. - : SAGE Publications. - 0961-2033 .- 1477-0962. ; 17:5, s. 394-399
-
Tidskriftsartikel (refereegranskat)abstract
- Patients with systemic lupus erythematosus (SLE) have an increased expression of type I interferon (IFN) regulated genes because of a continuous production of IFN-alpha. The cellular and molecular background to this IFN-alpha production has started to be elucidated during the last years, as well as the consequences for the innate and adaptive immune systems. Plasmacytoid dendritic cells (pDC) activated by immune complexes containing nucleic acids secrete type I IFN in SLE. Type I IFN causes differentiation of monocytes to myeloid-derived dendritic cell (mDC) and activation of autoreactive T and B cells. A new therapeutic option in patients with SLE is, therefore, inhibition of IFN-alpha, and recent data from a phase I clinical trial suggests that administration of neutralizing monoclonal antibodies against anti-IFN-alpha can ameliorate disease activity.
|
|
